Skip Navigation Links.
American Journal of Clinical Medicine Research. 2020, 8(2), 28-31
DOI: 10.12691/AJCMR-8-2-1
Original Research

Interrogating Gender Influence on the Prognosis of Acute Myeloid Leukaemia (AML)

Anwar A. Sayed1, 2,

1Department of Medical Microbiology and Immunology, Taibah University, Madinah, Saudi Arabia

2Department of Surgery and Cancer, Imperial College London, London, United Kingdom

Pub. Date: June 16, 2020
Full Text PDF

Cite this paper

Anwar A. Sayed. Interrogating Gender Influence on the Prognosis of Acute Myeloid Leukaemia (AML). American Journal of Clinical Medicine Research. 2020; 8(2):28-31. doi: 10.12691/AJCMR-8-2-1

Abstract

Acute myeloid leukaemia (AML) is a complex haematological malignancy characterised by a clonal expansion of the myeloid progenitor. Factors such as molecular/cytogenetic abnormalities influence the prognosis of this condition. However, gender predominance in AML and how it influences the outcome of the condition has not been studied. Raw data of 20,000 gene expressions in 180 AML patients were retrospectively retrieved from the Cancer Genome Atlas Genomic Data Commons portal. A linear model was fitted to calculate the impact of each gene on the overall survival. The coefficient value was set to 2, and a P value of < 0.01 was set to denote significance. Almost twice as many male patients were at poor cytogenetic risk than females regardless of their vital status. Male-abundant genes were highly expressed in patients with poor prognosis. However, none of these genes correlated with previously reported genes, such as FLT3. It was noted that many of the highly expressed genes in patients with poor prognosis were dominant in male patients. The lack of correlation between these genes and previously established genes indicate that male patients are at a higher risk of developing more severe forms of AML and carry a poorer prognosis than females.

Keywords

AML, gender, genetics, prognosis

Copyright

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References

[1]  Bullinger L, Döhner K, Döhner H. Genomics of Acute Myeloid Leukemia Diagnosis and Pathways. J Clin Oncol [Internet]. 2017 Mar 20; 35(9): 934-46.
 
[2]  Medeiros BC, Othus M, Fang M, Roulston D, Appelbaum FR. Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience. Blood. 2010 Sep 30; 116(13): 2224-8.
 
[3]  Saultz J, Garzon R. Acute Myeloid Leukemia: A Concise Review. J Clin Med [Internet]. 2016 Mar 5; 5(3): 33.
 
[4]  Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood [Internet]. 2009 Jul 30; 114(5): 937-51.
 
[5]  Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood [Internet]. 2010 Jan 21; 115(3): 453-74.
 
[6]  Byrd JC. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002 Dec 15; 100(13): 4325-36.
 
[7]  Mrózek K, Marcucci G, Nicolet D, Maharry KS, Becker H, Whitman SP, et al. Prognostic Significance of the European LeukemiaNet Standardized System for Reporting Cytogenetic and Molecular Alterations in Adults With Acute Myeloid Leukemia. J Clin Oncol. 2012 Dec 20; 30(36): 4515-23.
 
[8]  Grossman RL, Heath AP, Ferretti V, Varmus HE, Lowy DR, Kibbe WA, et al. Toward a Shared Vision for Cancer Genomic Data. N Engl J Med. 2016 Sep 22; 375(12): 1109-12.
 
[9]  Leukemia AM. Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia. N Engl J Med. 2013; 368(22): 2059-74.
 
[10]  R Development Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing. 2016.
 
[11]  Kelly LM. FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model. Blood. 2002 Jan 1; 99(1): 310-8.
 
[12]  Acharya UH, Halpern AB, Wu Q (Vicky), Voutsinas JM, Walter RB, Yun S, et al. Impact of region of diagnosis, ethnicity, age, and gender on survival in acute myeloid leukemia (AML). J Drug Assess. 2018; 7(1): 51-3.
 
[13]  Singh H, Asali S, Werner LL, DeAngelo DJ, Ballen KK, Amrein PC, et al. Outcome of older adults with cytogenetically normal AML (CN-AML) and FLT3 mutations. Leuk Res. 2011; 35(12): 1611-5.
 
[14]  Tawfik B, Pardee TS, Isom S, Sliesoraitis S, Winter A, Lawrence J, et al. Comorbidity, age, and mortality among adults treated intensively for acute myeloid leukemia (AML). J Geriatr Oncol. 2016; 7(1): 24-31.
 
[15]  Schnittger S, Schoch C, Kern W, Mecucci C, Tschulik C, Martelli MF, et al. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood. 2005; 106(12):3733-9.
 
[16]  Lin TL, Smith BD. Prognostically important molecular markers in cytogenetically normal acute myeloid leukemia. American Journal of the Medical Sciences. 2011.
 
[17]  Patel JP, Gönen M, Figueroa ME, Fernandez H, Sun Z, Racevskis J, et al. Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia. N Engl J Med. 2012 Mar 22; 366(12):1079-89.
 
[18]  Yazarloo F, Shirkoohi R, Mobasheri MB, Emami A, Modarressi MH. Expression analysis of four testis-specific genes AURKC, OIP5, PIWIL2 and TAF7L in acute myeloid leukemia: a gender-dependent expression pattern. Med Oncol. 2013 Mar 6; 30(1):368.
 
[19]  Chessells JM, Richards SM, Bailey CC, Lilleyman JS, Eden OB. Gender and treatment outcome in childhood lymphoblastic leukaemia: report from the MRC UKALL trials*. Br J Haematol. 1995 Feb; 89(2): 364-72.
 
[20]  Lee JP, Birnstein E, Masiello D, Yang D, Yang AS. Gender and ethnic differences in chronic myelogenous leukemia prognosis and treatment response: a single-institution retrospective study. J Hematol Oncol. 2009; 2(1): 30.
 
[21]  Eyre TA, Martinez‐Calle N, Hildyard C, Eyre DW, Plaschkes H, Griffith J, et al. Male gender is an independent predictor for worse survival and relapse in a large, consecutive cohort of elderly DLBCL patients treated with R‐ CHOP. Br J Haematol. 2019; 186(4):e94-e98.
 
[22]  Wendelbo Ø, Glenjen N, Bruserud Ø. Interleukin-7 (IL-7) in Patients Receiving Intensive Chemotherapy for Acute Myelogenous Leukemia: Studies of Systemic IL-7 Levels and IL-7 Responsiveness of Circulating T Lymphocytes. J Interf Cytokine Res. 2002 Oct; 22(10): 1057-65.
 
[23]  Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, et al. Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring. Science (80). 1999; 286(5439): 531-7.
 
[24]  Thorsteinsdottir U, Mamo A, Kroon E, Jerome L, Bijl J, Lawrence HJ, et al. Overexpression of the myeloid leukemia-associated Hoxa9 gene in bone marrow cells induces stem cell expansion. Blood. 2002; 99(1): 121-9.